en_US EN
en_US EN es_MX ES

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Home / Managing RKD / Clinical Trials

Clinical Trials

Participating in a clinical trial gives you access to cutting-edge treatments and expert care, while helping advance research that could benefit countless others. You’ll be closely monitored by top physicians throughout the trial to ensure your safety, and if the treatment proves effective, you could be among the first to benefit. Your involvement today helps shape the future of kidney disease care. To learn more about current trials and how to get involved, visit our clinical trial resources.

Find a Clinical Trial That is Right for You

Use our clinical trial matching tool to see if you match to any rare kidney diseases (RKD) clinical trials. Just answer a few quick questions, and we’ll help connect you to trials that may be right for you. Your participation could lead to better treatments and hope for the RKD community.

What is your diagnosis?
Please assume that the conditions listed are "Primary" or Idiopathic". If you have a genetic mutation, we will consider it to be "Primary" for the purposes of the question.
Have you ever had a kidney transplant?
Are you currently on dialysis?
Are you currently spilling protein?
Did you have a biopsy to confirm your diagnosis?
Search for trials near me:
What is your current eGFR?
What was your latest UPCR (urine protein to creatinine ratio)?
What treatments have you taken for your disease?
Are you considered one of the following?
Are you currently on the transplant wait-list?
Disclaimer
The “Am I A Match?” tool is designed solely to help filter the clinical trials listed below based on your responses.

Filter Results By

Download List of

Clinical Trials

Generate a custom PDF of clinical trials based on your selected filters. Choose disease types or other filter options, and download a tailored list that meets your search criteria.

Download PDF

Want to Learn More about Clinical Trials?

Explore these resources to better understand what to expect during a trial, so you can feel informed.

View Resources

Featured

KIND
The KIND study is testing the safety, efficacy, and pharmacokinetics of paricalcitol oral solution in participants of ages 0 to 9 years that have been diagnosed with...

Currently Enrolling

Interventional

FSGS

IgA NEPHROPATHY

Pediatric

Learn More
ACTION3
The ACTION3 Study will examine if the investigational medicine, DMX-200 (repagermanium), reduces the amount of proteinuria (protein in your urine) and slows the decline of...

Currently Enrolling

Interventional

FSGS

Adult

Pediatric

Learn More

All Clinical Trials

Download Clinical Trials
Searching for nearby trials...
This may take a moment
NOBLE
The study is evaluating the safety and effectiveness of an investigational, targeted C3 inhibitor called pegcetacoplan in adults who have C3G or IC-MPGN recurrence after...

Enrollment Closed

Interventional

C3 GLOMERULOPATHY

IC-MPGN

Adult

Learn More
VALIANT
The purpose of this study is to assess the efficacy and safety of twice weekly pegcetacoplan compared to placebo in patients with C3G or IC-MPGN, on the basis of a reduction...

Enrollment Closed

Interventional

C3 GLOMERULOPATHY

IC-MPGN

Adult

Pediatric

Learn More
APPRECIATE Study
The purpose of this study is to learn more about the safety, tolerability, and effectiveness of AZD2373 and to better understand AMKD and associated health problems.

Currently Enrolling

Interventional

APOL1

FSGS

Adult

Learn More
PREVAIL
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who...

Currently Enrolling

Interventional

IgA NEPHROPATHY

Adult

Learn More
CARE and JUSTICE
JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.

Currently Enrolling

Interventional

APOL1

FSGS

Adult

Learn More
ASSIST
A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2 inhibitor.

Enrollment Closed

Interventional

APOL1

FSGS

Adult

Learn More
CureGN
Cure Glomerulonephropathy (CureGN) is a multicenter five-year observational study of glomerular disease patients.

Currently Enrolling

Observational

ALPORT SYNDROME

APOL1

C3 GLOMERULOPATHY

FSGS

IC-MPGN

IgA NEPHROPATHY

MEMBRANOUS

MEMBRANOUS NEPHROPATHY

MINIMAL CHANGE DISEASE

NEPHROTIC SYNDROME

Adult

Pediatric

Learn More
The IgAN Bridge Study
The purpose of this study is to collect observational data through a mobile app, providing insights into the burden of disease and treatment patterns in IgAN.

Currently Enrolling

Observational

IgA NEPHROPATHY

Adult

Pediatric

Learn More
Genetic Study for Kidney Patients
The Laboratory of Inherited Kidney Disease at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts, directed by Dr. Martin Pollak, seeks...

Currently Enrolling

Observational

FSGS

NEPHROTIC SYNDROME

Adult

Pediatric

Learn More
I CAN Clinical Study for Patients with IgAN
The purpose of the I CAN Study is to evaluate the safety and effectiveness of ravulizumab compared with placebo to potentially help manage symptoms in adults who have IgAN

Currently Enrolling

Interventional

IgA NEPHROPATHY

Adult

Learn More
I CAN Junior
To evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) with Primary Immunoglobulin A...

Currently Enrolling

Interventional

IgA NEPHROPATHY

Pediatric

Learn More
The Liposorber Trial for Pediatric Patients with FSGS
Liposorber LA-15 System is a blood processing system used outside of the body. This device removes certain lipoproteins (LDL/BDL) from the patient's blood. The Liposorber...

Currently Enrolling

Interventional

FSGS

Pediatric

Learn More
The Liposorber Trial for Adults with FSGS
Liposorber LA-15 System is a blood processing system used outside of the body. This device removes certain lipoproteins (LDL/BDL) from the patient's blood. The Liposorber...

Currently Enrolling

Interventional

FSGS

Adult

Learn More
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
This is a phase-2 clinical study, which means it tests whether a new medicine in a small group of people with a specific illness works well and is safe before larger studies...

Currently Enrolling

Interventional

FSGS

Adult

Learn More
IGNAZ
The IGNAZ Study is looking at the safety and effectiveness of Felzartamab in adults 18 to 80 years old with IgA nephropathy. Researchers want to compare different doses of...

Enrollment Closed

Interventional

IgA NEPHROPATHY

Adult

Learn More
NefXtend
The study assesses the efficacy and safety of extended TARPEYO® treatment in adult participants who have completed 9 months of TARPEYO 16 mg daily treatment. The study...

Currently Enrolling

Interventional

IgA NEPHROPATHY

Adult

Learn More
NEPTUNE
The purpose of this study is to gather long-term observational data in order to help understand the biology behind nephrotic syndrome.

Currently Enrolling

Observational

ALPORT SYNDROME

APOL1

C3 GLOMERULOPATHY

FSGS

IC-MPGN

IgA NEPHROPATHY

MEMBRANOUS

MEMBRANOUS NEPHROPATHY

MINIMAL CHANGE DISEASE

NEPHROTIC SYNDROME

Adult

Pediatric

Learn More
kidNEY-VNS
This study seeks to explore taVNS as a potential, novel treatment for children with steroid resistant nephrotic syndrome (SRNS).

Enrollment Closed

Interventional

MINIMAL CHANGE DISEASE

NEPHROTIC SYNDROME

Pediatric

Learn More
kidNEY-VNS for FRNS
This study seeks to explore taVNS as a potential, novel treatment for children with frequently relapsing nephrotic syndrome (FRNS).

Currently Enrolling

Interventional

FSGS

NEPHROTIC SYNDROME

Pediatric

Learn More
APPARENT
The purpose of this study is to assess the efficacy and safety of iptacopan compared to placebo (both administered in combination with stand of care) in patients with...

Currently Enrolling

Interventional

IC-MPGN

Adult

Learn More
APPEAR-C3G
The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in...

Currently Enrolling

Interventional

C3 GLOMERULOPATHY

Pediatric

Learn More
BEYOND
The purpose of this study is to evaluate the safety and efficacy of BION-1301 in adults with IgA nephropathy.

Currently Enrolling

Interventional

IgA NEPHROPATHY

Adult

Learn More
APRICOT
Study to assess the efficacy, pharmacokinetics (PK), safety and tolerability of iptacopan in pediatric patients with primary IgAN

Interventional

IgA NEPHROPATHY

Pediatric

Learn More
Prepare-NS
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome. Interviews with patients...

Currently Enrolling

Observational

FSGS

MEMBRANOUS NEPHROPATHY

MINIMAL CHANGE DISEASE

NEPHROTIC SYNDROME

Adult

Pediatric

Learn More
Protein in Urine
Observational study that is one visit that after the Informed consent is signed, medical history is reviewed, and blood and urine specimens are collected. Optional genetic...

Currently Enrolling

Observational

APOL1

MINIMAL CHANGE DISEASE

NEPHROTIC SYNDROME

Adult

Learn More
R3R01: AS-FSGS
A Phase II, Multi-center, Open-Label Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of R3R01 in Alport Syndrome Patients with uncontrolled...

Enrollment Closed

Interventional

ALPORT SYNDROME

FSGS

Adult

Pediatric

Learn More
RAINIER
RAINIER is a clinical research study for adults with immunoglobulin A nephropathy (IgAN).

Enrollment Closed

Interventional

IgA NEPHROPATHY

Adult

Learn More
REBOOT
The REBOOT study is a randomized, double-blind, placebo-controlled, phase II, multicenter study for adults with primary membranous nephropathy). REBOOT will investigate...

Currently Enrolling

Interventional

MEMBRANOUS NEPHROPATHY

Adult

Learn More
RESULT Trial
The purpose of this study is to measure the change in proteinuria and its impact on the rates of partial and complete remission in patients with primary FSGS or MCD with...

Currently Enrolling

Interventional

FSGS

MINIMAL CHANGE DISEASE

Adult

Pediatric

Learn More
A.M.IgA. Study
The main purpose of this phase 3 randomized, placebo controlled, double-blind clinical trial is to evaluate the efficacy of mezagitamab as compared to placebo as add-on...

Currently Enrolling

Interventional

IgA NEPHROPATHY

Adult

Learn More
The INShore Study
This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate...

Enrollment Closed

Interventional

NEPHROTIC SYNDROME

Adult

Pediatric

Learn More
The Rare Genomes Project
The Rare Genomes Project aims to increase rare and undiagnosed families’ access to genomic research, empowering patients to directly accelerate the pace of rare disease...

Currently Enrolling

Observational

ALPORT SYNDROME

APOL1

C3 GLOMERULOPATHY

FSGS

IC-MPGN

IgA NEPHROPATHY

MEMBRANOUS

MEMBRANOUS NEPHROPATHY

MINIMAL CHANGE DISEASE

NEPHROTIC SYNDROME

Adult

Pediatric

Learn More
The TANGO Study
The TANGO study aims to create a large international network of centers to study glomerular disease (GN) recurrence after renal transplantation.

Currently Enrolling

Observational

ALPORT SYNDROME

APOL1

C3 GLOMERULOPATHY

FSGS

IC-MPGN

IgA NEPHROPATHY

MEMBRANOUS

MEMBRANOUS NEPHROPATHY

MINIMAL CHANGE DISEASE

NEPHROTIC SYNDROME

Adult

Pediatric

Learn More
EPPIK (IgAN, IgAV, Alport Syndrome)
The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria...

Currently Enrolling

Interventional

ALPORT SYNDROME

IgA NEPHROPATHY

Pediatric

Learn More
EPPIK (FSGS & MCD)
The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria...

Currently Enrolling

Interventional

FSGS

MINIMAL CHANGE DISEASE

Pediatric

Learn More
ORIGIN
The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.

Enrollment Closed

Interventional

IgA NEPHROPATHY

Adult

Learn More
AMPLITUDE
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 12 years and older with apolipoprotein L1...

Currently Enrolling

Interventional

APOL1

Adult

Pediatric

Learn More
WAL0921-02
Study WAL0921-02 is an adaptive, prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate WAL0921 in subjects with glomerular kidney diseases...

Currently Enrolling

Interventional

FSGS

IgA NEPHROPATHY

MEMBRANOUS NEPHROPATHY

MINIMAL CHANGE DISEASE

Adult

Learn More
Headline decoration line

Careers

Explore career opportunities at NephCure, where passion meets purpose. Our dedicated team is committed to advancing research, supporting patients, and raising awareness for rare kidney diseases. Explore rewarding career opportunities today.

JOIN THE TEAM

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.
NephCure Logo

INTRO TO RKD

Overview
Types of RKD
Navigating New Diagnosis
Pediatric Care
End-Stage Kidney Disease

SUPPORT

Patient Navigation Services
Online Patient Community
Patient Stories
Support Groups
Resources

MANAGING RKD

Find a Specialist
Clinical Trials
Treatment Options
RKD & Mental Health
Diet & Nutrition
Genetic Testing

LEGAL

Careers
Privacy Policy
Policies & Disclaimers
Financials

ABOUT US

Our Impact
What We Do
Team
Current Partnerships
News
Contact Us

GET INVOLVED

Volunteer
Events
Advocacy
Find your Local Community
Ways to Give

Our Mission

NephCure’s mission is to empower people with rare, protein-spilling kidney disease to take charge of their health, while leading the revolution in research, new treatments, and care.

Find Us On

NephCure is a registered non-profit (501c3) tax-exempt charitable organization. EIN # 38-3569922.
© Copyright 2024 NephCure, Inc. All rights reserved worldwide. NephCure, and the logo, are federally registered trademarks of NephCure, Inc.